Adding to its portfolio in an increasingly attractive therapeutic area and hoping to bring back patients after a landmark Women's Health Initiative (WHI) study on estrogen treatments, Amag Pharmaceuticals Inc. signed a deal with Endoceutics Inc. that brings U.S. commercial rights to Intrarosa (prasterone), an FDA-cleared, daily non-estrogen product for the treatment of moderate-to-severe dyspareunia (pain during intercourse), a common symptom of vulvar and vaginal atrophy (VVA) due to menopause.